[go: up one dir, main page]

WO2023178339A3 - Methods and compositions for treating tnnt2 related cardiomyopathy with a viral vector - Google Patents

Methods and compositions for treating tnnt2 related cardiomyopathy with a viral vector Download PDF

Info

Publication number
WO2023178339A3
WO2023178339A3 PCT/US2023/064673 US2023064673W WO2023178339A3 WO 2023178339 A3 WO2023178339 A3 WO 2023178339A3 US 2023064673 W US2023064673 W US 2023064673W WO 2023178339 A3 WO2023178339 A3 WO 2023178339A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cardiomyopathy
compositions
tnnt2
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/064673
Other languages
French (fr)
Other versions
WO2023178339A2 (en
Inventor
Barry John Byrne
Manuela CORTI
Widler CASY
Adam Cockrell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida
University of Florida Research Foundation Inc
Aavantibio Inc
Original Assignee
University of Florida
University of Florida Research Foundation Inc
Aavantibio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida, University of Florida Research Foundation Inc, Aavantibio Inc filed Critical University of Florida
Priority to CA3254775A priority Critical patent/CA3254775A1/en
Priority to JP2024555341A priority patent/JP2025509828A/en
Priority to EP23771729.3A priority patent/EP4493702A2/en
Priority to IL315697A priority patent/IL315697A/en
Priority to KR1020247034272A priority patent/KR20250007509A/en
Priority to US18/847,734 priority patent/US20250195694A1/en
Priority to AU2023234604A priority patent/AU2023234604A1/en
Publication of WO2023178339A2 publication Critical patent/WO2023178339A2/en
Publication of WO2023178339A3 publication Critical patent/WO2023178339A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present disclosure relates to compositions and methods for the treatment of cardiomyopathy. Several embodiments provided for herein relate to virally-mediated transfer of a gene to host cells to induce expression of an encoded polypeptide, protein or other product to host in order to ameliorate one or more symptoms of the cardiomyopathy. In several embodiments, the methods and compositions relate to recombinant adeno-associated virus particles encoding human TNNT2 in order to treat cardiomyopathies, including dilated cardiomyopathy or hypertrophic cardiomyopathy.
PCT/US2023/064673 2022-03-18 2023-03-18 Methods and compositions for treating tnnt2 related cardiomyopathy with a viral vector Ceased WO2023178339A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA3254775A CA3254775A1 (en) 2022-03-18 2023-03-18 METHODS AND COMPOSITIONS FOR TREATING TNNT2-RELATED CARDIOMYOPATHY WITH A VIRAL VECTOR
JP2024555341A JP2025509828A (en) 2022-03-18 2023-03-18 Methods and compositions for treating TNNT2-associated cardiomyopathy with viral vectors
EP23771729.3A EP4493702A2 (en) 2022-03-18 2023-03-18 Methods and compositions for treating tnnt2 related cardiomyopathy with a viral vector
IL315697A IL315697A (en) 2022-03-18 2023-03-18 Methods and compositions for treating tnnt2 related cardiomyopathy with a viral vector
KR1020247034272A KR20250007509A (en) 2022-03-18 2023-03-18 Methods and compositions for treating TNNT2-associated cardiomyopathy using viral vectors
US18/847,734 US20250195694A1 (en) 2022-03-18 2023-03-18 Methods and compositions for treating tnnt2 related cardiomyopathy with a viral vector
AU2023234604A AU2023234604A1 (en) 2022-03-18 2023-03-18 Methods and compositions for treating tnnt2 related cardiomyopathy with a viral vector

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263321264P 2022-03-18 2022-03-18
US63/321,264 2022-03-18

Publications (2)

Publication Number Publication Date
WO2023178339A2 WO2023178339A2 (en) 2023-09-21
WO2023178339A3 true WO2023178339A3 (en) 2023-11-16

Family

ID=88024553

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/064673 Ceased WO2023178339A2 (en) 2022-03-18 2023-03-18 Methods and compositions for treating tnnt2 related cardiomyopathy with a viral vector

Country Status (8)

Country Link
US (1) US20250195694A1 (en)
EP (1) EP4493702A2 (en)
JP (1) JP2025509828A (en)
KR (1) KR20250007509A (en)
AU (1) AU2023234604A1 (en)
CA (1) CA3254775A1 (en)
IL (1) IL315697A (en)
WO (1) WO2023178339A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025214477A1 (en) * 2024-04-12 2025-10-16 Skyline Therapeutics (Shanghai) Co., Ltd. Treatment of genetic cardiomyopathies with aav gene therapy vectors
WO2025226841A1 (en) * 2024-04-24 2025-10-30 Kate Therapeutics, Inc. Gene therapy approach for treating disorders associated with tnnt2
WO2025235807A1 (en) * 2024-05-10 2025-11-13 Solid Biosciences, Inc. Compositions and methods to improve graft survival

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140256799A1 (en) * 2013-02-28 2014-09-11 City Of Hope REPLICATION CAPABLE rAAV VECTORS ENCODING INHIBITORY siRNA AND METHODS OF THEIR USE
US20160108430A1 (en) * 2013-04-17 2016-04-21 Universitätsklinikum Hamburg-Eppendorf Gene-therapy vectors for treating cardiomyopathy
WO2020198337A1 (en) * 2019-03-25 2020-10-01 Ohio State Innovation Foundation Engineered mrna sequences and uses thereof
WO2021154923A2 (en) * 2020-01-29 2021-08-05 Voyager Therapeutics, Inc. Methods and systems for producing aav particles
WO2021163357A2 (en) * 2020-02-13 2021-08-19 Tenaya Therapeutics, Inc. Gene therapy vectors for treating heart disease
WO2023108159A1 (en) * 2021-12-10 2023-06-15 University Of Florida Research Foundation, Incorporated Methods and compositions for treating bag-3 related cardiomyopathy with a viral vector

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140256799A1 (en) * 2013-02-28 2014-09-11 City Of Hope REPLICATION CAPABLE rAAV VECTORS ENCODING INHIBITORY siRNA AND METHODS OF THEIR USE
US20160108430A1 (en) * 2013-04-17 2016-04-21 Universitätsklinikum Hamburg-Eppendorf Gene-therapy vectors for treating cardiomyopathy
WO2020198337A1 (en) * 2019-03-25 2020-10-01 Ohio State Innovation Foundation Engineered mrna sequences and uses thereof
WO2021154923A2 (en) * 2020-01-29 2021-08-05 Voyager Therapeutics, Inc. Methods and systems for producing aav particles
WO2021163357A2 (en) * 2020-02-13 2021-08-19 Tenaya Therapeutics, Inc. Gene therapy vectors for treating heart disease
WO2023108159A1 (en) * 2021-12-10 2023-06-15 University Of Florida Research Foundation, Incorporated Methods and compositions for treating bag-3 related cardiomyopathy with a viral vector

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TOWNSEND, PJ ET AL ET AL.: "Human Cardiac Troponin T: Identification of Fetal Isoforms and assignment of the TNNT2 Locus to Chromosome 1q", GENOMICS, vol. 21, no. 2, 15 May 1994 (1994-05-15), pages 311 - 316, XP024796242, DOI: 10.1006/geno.1994.1271 *
YAMAGUCHI YUYA, TANIHATA JUN, BABA SHUNSUKE, MORIMOTO SACHIO, MINAMISAWA SUSUMU: "Wild‐type troponin T gene overexpression in mice with troponin T mutant‐induced dilated cardiomyopathy partially rescued cardiac pathology", THE FASEB JOURNAL, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, US, vol. 35, no. S1, 1 May 2021 (2021-05-01), US, pages 2, XP009550733, ISSN: 0892-6638, DOI: 10.1096/fasebj.2021.35.S1.02274 *

Also Published As

Publication number Publication date
AU2023234604A1 (en) 2024-10-10
CA3254775A1 (en) 2023-09-21
KR20250007509A (en) 2025-01-14
WO2023178339A2 (en) 2023-09-21
EP4493702A2 (en) 2025-01-22
US20250195694A1 (en) 2025-06-19
IL315697A (en) 2024-11-01
JP2025509828A (en) 2025-04-11

Similar Documents

Publication Publication Date Title
WO2023178339A3 (en) Methods and compositions for treating tnnt2 related cardiomyopathy with a viral vector
WO2023178337A3 (en) Methods and compositions for treating rbm20 related cardiomyopathy with a viral vector
KR102043426B1 (en) Anti-inflammatory Peptides and Composition comprising the same
JP2017221201A5 (en)
JP2018514190A5 (en)
JP2013516427A5 (en)
WO2022232327A3 (en) Aav capsids and uses thereof
MX2022012279A (en) Aav capsids variants and uses thereof.
WO2020219766A8 (en) Compositions useful in treatment of rett syndrome
CR20230363A (en) Synergistic effect of smn1 and mir-23a in treating spinal muscular atrophy
BR112022004027A2 (en) Methods to treat ocular neovascular diseases using aav2 variants encoding aflibercept
EP2465935A3 (en) Recombinant human interferon-like proteins
MX2023006694A (en) Treatment of danon disease.
JPWO2021007529A5 (en)
WO2023178338A3 (en) Methods and compositions for treating tmem43 related cardiomyopathy with a viral vector
JP2020127419A5 (en)
CN101878226B (en) Novel Synthetic Peptides Substituted by Arginine and Their Applications
MX2024004723A (en) Compositions useful in treatment of cdkl5 deficiency disorder (cdd).
CN107698665B (en) An antiviral polypeptide, encoding gene, vector, host bacteria and application
MY198257A (en) Gene Therapy With Dysferlin Dual Vectors
MX2022014255A (en) Compositions useful for treatment of pompe disease.
CA3245159A1 (en) Novel proteins and nucleic acid sequences and use thereof in the prophylaxis and/or treatment of congenital muscular dystrophies
CN111518898A (en) Application of Opa1 allotrope protein in regulating and controlling proliferation capacity of liver cancer cells
CN117925544A (en) Porcine reproductive and respiratory syndrome virus attenuated strain, and preparation method and application thereof
MX2024008847A (en) Recombinant orthopox viral vector encoding immunostimulatory proteins for cancer treatment.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23771729

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: P2024-02429

Country of ref document: AE

Ref document number: 315697

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2024555341

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: AU2023234604

Country of ref document: AU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112024019069

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2023234604

Country of ref document: AU

Date of ref document: 20230318

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020247034272

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2023771729

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023771729

Country of ref document: EP

Effective date: 20241018

WWE Wipo information: entry into national phase

Ref document number: 11202406391P

Country of ref document: SG

ENP Entry into the national phase

Ref document number: 112024019069

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20240916

WWP Wipo information: published in national office

Ref document number: 18847734

Country of ref document: US